Michelle Doig

Partner, Head of Corporate Development at Omega Funds

Director

Michelle joined Omega Funds in 2016. She has more than 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Michelle currently serves on the Board of Directors of Artios Pharma and BBOT and is a Board Observer at Arrakis Therapeutics.

Previously, Michelle was Director of Corporate Finance at Third Rock Ventures, where she supported numerous portfolio companies through their initial private and public financings. Prior to joining Third Rock, Michelle was a Principal at Abingworth in London and Boston. She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York and Morgan Stanley in Toronto and New York. Michelle has executed more than 50 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, MedImmune, Millennium, Illumina, and Sepracor. Michelle graduated with an Honor’s degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario in London.